Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.
Moyle
Graeme J
GJ
HIV Research, Chelsea & Westminster Hospital, London, UK.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D015224:Dideoxynucleosides / Q000737:chemistry / Q000627:therapeutic use*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D019259:Lamivudine / Q000737:chemistry / Q000627:therapeutic use*; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D015215:Zidovudine / Q000737:chemistry / Q000627:therapeutic use*; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; C418262:abacavir, lamivudine, and zidovudine drug combination; D000099227:Abacavir